Your session is about to expire
← Back to Search
Behavioral Intervention
Communication Bridge™ for Primary Progressive Aphasia (CB3 Trial)
Phase 2
Waitlist Available
Led By Emily Roglaski, PhD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18+ years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 assessment time points through study completion, an average of 1 year, including change over time
Awards & highlights
CB3 Trial Summary
This trial will investigate the effects of two different treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The goal is to determine how speech-language therapy can improve communication abilities in individuals
Who is the study for?
This trial is for adults with mild to moderate Primary Progressive Aphasia (PPA), including conditions like Pick's Disease and Frontotemporal Dementia. Participants should be able to engage in speech-language therapy.Check my eligibility
What is being tested?
The study compares two evidence-based speech-language therapies using a randomized controlled design, aiming to understand their impact on communication abilities in individuals with PPA.See study design
What are the potential side effects?
Since the interventions are non-medical therapies focused on improving communication, no traditional side effects like those seen with medications are expected.
CB3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
CB3 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 assessment time points through study completion, an average of 1 year, including change over time
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 assessment time points through study completion, an average of 1 year, including change over time
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Communication Participation Person Centered Goals
CB3 Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Communication Bridge™Experimental Treatment1 Intervention
Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
Group II: Evidence-Based Impairment FocusedActive Control1 Intervention
The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Communication Bridge™
2018
N/A
~110
Find a Location
Who is running the clinical trial?
National Institute on Aging (NIA)NIH
1,692 Previous Clinical Trials
28,027,014 Total Patients Enrolled
University of ChicagoLead Sponsor
1,012 Previous Clinical Trials
733,870 Total Patients Enrolled
Western University, CanadaOTHER
242 Previous Clinical Trials
57,307 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger